On September 22, METIS TECHBIO-P rose 5.15% in regular trading, trading at 17.98 HKD/share, with turnover of approximately 40.87 million HKD. The stock has accumulated over 35% gains over the past several trading sessions, consistently leading the AI pharmaceutical sector.

Multiple catalysts continue to fuel the rally. On the policy front, the 15th Five-Year Plan has officially designated AI-driven drug development as a strategic priority, explicitly calling for the cultivation of high-value AI pharma application scenarios. On the business side, the company recently signed a joint venture agreement with Zhaoyan Bio to establish NanoTai Zhiyao, an mRNA drug R&D and industrialization platform. Under the agreement, METIS TECHBIO contributes AI-driven mRNA sequence design and nano-delivery capabilities via its NanoForge platform, which has achieved targeted delivery to eight key human organs and tissues.

These developments build on a series of milestones including the company's inclusion in the Stock Connect program effective September 7, a strategic partnership with Greenleaf Pharma, and explosive H1 financial results showing revenue of RMB 154 million, up over 133-fold year-over-year, surpassing full-year prior revenue by 47%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)